Waiting for a recovery in the orthopedic market isn't exactly
waiting for Godot, but it has been frustrating all the same. Between
modest (but steady) price pressure, lower patient volumes, and more
assertive hospital customers, major ortho companies like Zimmer (NYSE: ZMH ) , Stryker (NYSE: SYK ) , and Johnson & Johnson (NYSE: JNJ )
have had their work cut out to generate better results from what has
historically been one of the largest medical device markets, and a
profitable one at that.
As the second quarter earnings cycle revs up, Biomet
has started things off with its fiscal fourth quarter report. Although
there's nothing in the report that should worry Zimmer investors (Zimmer
is in the process of trying to get regulatory approvals for its
acquisition of Biomet), there is likewise not a lot to really encourage
investors hoping for a major return to growth in the quarter.
Read more here:
Is This Huge Market Slowing Down?
No comments:
Post a Comment